Taipeibio Wins Third Prize in RESI Innovation Challenge Boston 2018
Latest News
Fulbright Specialist Program sponsored by Taipeibio.
Fulbright Specialist Program – Prof. John F. Bowley, Chief Boston VA Healthcare System, sponsored by United States Department of State Bureau of Educational and Cultural Affairs, Taipeibio, and Shuang-Ho Hospital, Ministry of Health and Welfare, Taiwan
DrugDangers
Thousands of Americans turn to medical attention to help improve their quality of life and relieve them of pain and suffering. Medications and implant surgeries, such as hip or knee replacement, can change and even save lives.
Zimmer Completes Combination with Biomet
WARSAW, Ind., June 24, 2015 /PRNewswire/ -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today announced that, following the receipt of U.S. Federal Trade Commission clearance, Zimmer has completed the acquisition of Biomet in a cash and equity transaction currently valued at approximately $14.0 billion. In connection with the combination, Zimmer has changed its corporate name to Zimmer Biomet Holdings, Inc. The Company will trade on the New York Stock Exchange and the SIX Swiss Exchange under the ticker symbol ZBH beginning June 29, 2015.
Medtronic Completes Acquisition of Covidien
DUBLIN, Ireland - January 26, 2015 - Medtronic plc (NYSE: MDT), a global leader in medical technology, services and solutions, announced today that it has successfully completed the previously announced acquisition of Covidien plc (NYSE: COV). Under the terms of the acquisition agreement, Medtronic, Inc. and Covidien plc are now combined under Medtronic plc. Shares of Medtronic plc are expected to begin trading on the New York Stock Exchange (NYSE) under the symbol "MDT" on Tuesday, January 27, 2015.
Press Release
WALTHAM.. Mass... Feb. 02.. 2016 ..GLOBE NEWSWIRE.. -- Histogenics Corporation ..Histogenics.. ..Nasdaq:HSGX.... a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space.. announced that as of February 2.. 2016 it had enrolled 123.. or just over half.. of the 245 patients required to complete enrollment of its ongoing NeoCart Phase 3 clinical trial. This trial is being conducted under a Special Protocol Assessment ..SPA.. with the United States Food and Drug Administration ..FDA...
DEPUY SYNTHES TRAUMA LAUNCHES NEW BIOLOGIC IMPLANT
San Diego, CA – October 8, 2015 -DePuy Synthes Trauma* announced today the U.S. launch of CONFORM® Flex with Q-PACK® Technology**, the only pre-hydrated demineralized cancellous bone tissue matrix designed for use in trauma-related extremity procedures ,(foot and ankle, hand and wrist,), including fusion, and for filling bone voids. The announcement was made here at the 2015 Orthopaedic Trauma Association ,(OTA) Annual Meeting.